Treatment of psoriasis with deucravacitinib
Correction of Psoriatic T Cell Signatures by Deucravacitinib
This study is testing how well a new medication called deucravacitinib can change immune cell behavior in people with moderate to severe psoriasis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Drugs / interventions | deucravacitinib |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05858645 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of deucravacitinib, a TYK2 inhibitor, on immune cell function in patients with moderate to severe psoriasis. It is a one-arm, open-label study involving 25 participants who will undergo biopsy and blood sampling before and during treatment. The goal is to analyze the molecular profiles of immune cells to determine how deucravacitinib alters psoriatic signatures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with moderate to severe psoriasis.
Not a fit: Patients with severe immunodeficiency, active infections, or those on systemic immunosuppressives may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of psoriasis by correcting immune cell dysfunction.
How similar studies have performed: Other studies have shown promise with TYK2 inhibitors in treating autoimmune conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age or older 2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above) Exclusion Criteria: 1. taking systemic immunosuppressives in the last 12 weeks 2. pregnancy 3. severe immunodeficiency (either from genetic or infectious causes). 4. tuberculosis or other active serious infection 5. active systemic malignancy. 6. breast-feeding 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Raymond Cho, MD, PhD — University of California, San Francisco
- Study coordinator: Raymond Cho, MD, PhD
- Email: rashes@ucsf.edu
- Phone: 415 575 0524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.